The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches

Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cell...

Full description

Saved in:

Bibliographic Details
Published in:	Cytotherapy (Oxford, England) Vol. 16; no. 7; pp. 927 - 933
Main Authors:	Jain, Natasha A., Lu, Kit, Ito, Sawa, Muranski, Pawel, Hourigan, Christopher S., Haggerty, Janice, Chokshi, Puja D., Ramos, Catalina, Cho, Elena, Cook, Lisa, Childs, Richard, Battiwalla, Minoo, Barrett, A. John
Format:	Journal Article
Language:	English
Published:	England Elsevier Inc 01.07.2014
Subjects:	Adolescent Adult Advanced Basic Science Aged antiviral cellular therapy Child CMV reactivation Cost of Illness Cytomegalovirus - genetics Cytomegalovirus - pathogenicity Cytomegalovirus Infections - economics Cytomegalovirus Infections - pathology Cytomegalovirus Infections - virology economic cost Female Hematologic Neoplasms - mortality Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - economics Humans Male Middle Aged Other pre-emptive therapy Risk Factors T-Lymphocytes - immunology T-Lymphocytes - pathology T-Lymphocytes - virology Tissue Donors Transplantation, Homologous - adverse effects Transplantation, Homologous - economics Virus Activation - genetics economic cost CMV reactivation pre-emptive therapy antiviral cellular therapy
ISSN:	1465-3249, 1477-2566, 1477-2566
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!